Eyevensys has added $12m to its coffers, having previously procured $30m in a series B round backed by Inserm Transfert in early 2020.
Eyevensys, a France-based eye disease therapy developer based on research at Paris Descartes University, has picked up $12m in a series B-plus round led by Korea Investment Partners.
Unnamed, existing backers also took part in the round.
Founded in 2008, Eyevensys is working on non-viral gene therapies for retinal and ophthalmological diseases. It will use the money to advance its programmes, including a potential treatment for wet age-related macular degeneration.
Patricia Zilliox, CEO of Eyevensys, said: “We…
